These kits are manufactured in accordance with the 98/79 EC directive for in vitro diagnostic devices. Only CE marked products can be used for diagnostic applications in Europe.
These kits are intended for in vitro diagnostic use.
These kits are for research use only and are not intended to be used for diagnostic procedures.
Federal Drug Administration, FDA validates diagnostic kits for in vitro diagnostic use in the United States.
Biological risk products.
Storage between 2 and 8 ° C.
Reactive in liquid form.
Reactive in lyophilized form.
Reactive in frozen form.
Stability after opening at 2-8 ° C.
Products that can be refrozen.
Stability 12 months after refreezing at -20 ° C.
1 x 1.0 mL
Price list, safety data sheets and notices are accessible to our registered customers.
Arixtra is obtained by chemical synthesis. It is an injectable anticoagulant that selectively inhibits FXa. In low doses it is used in the preventive treatment of venous thromboembolic accidents and in high doses it is used in the treatment of venous thrombosis.
Special plasmas are derived from patients with a congenital deficiency, severe or moderate, or presenting a particular profile. No buffer or preservatives are added. Quickly frozen at -80° C, the plasma maintains perfectly intact the matrix. All plasmas are stable when stored at -40° C to -80° C. We carefully pack with dry ice during shipment. No additive or preservative. Expiry date > 1 year. Plastic vials.